Page last updated: 2024-11-05

uridine diphosphate galactose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uridine diphosphate galactose (UDP-galactose) is a nucleotide sugar that plays a crucial role in the biosynthesis of galactose-containing molecules, including lactose, glycoproteins, and glycolipids. It is synthesized from UDP-glucose through the action of the enzyme UDP-glucose 4-epimerase. UDP-galactose is a substrate for various enzymes, including galactosyltransferases, which transfer galactose to acceptor molecules in the synthesis of complex carbohydrates. The study of UDP-galactose is significant in understanding the pathways of carbohydrate metabolism, the regulation of glycoprotein and glycolipid biosynthesis, and the genetic disorders associated with galactose metabolism.'
```

Uridine Diphosphate Galactose: A nucleoside diphosphate sugar which can be epimerized into UDPglucose for entry into the mainstream of carbohydrate metabolism. Serves as a source of galactose in the synthesis of lipopolysaccharides, cerebrosides, and lactose. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

UDP-alpha-D-galactose : A UDP-D-galactose in which the anomeric centre of the galactose moiety has alpha-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID18068
CHEMBL ID439009
CHEBI ID67119
SCHEMBL ID1521203
MeSH IDM0022346

Synonyms (62)

Synonym
gtpl1782
uridine diphosphogalactose
udpgal
uridine pyrophosphogalactose
udp galactose
uridinediphosphogalactose
uridine diphosphate galactose
gdu ,
galactose-uridine-5'-diphosphate
udp-gal
uridine 5'-pyrophosphate, d-galactosyl ester
udp-galactopyranose
uridinediphosphate galactose
uridine 5'-diphosphate galactose
uridine pyrophosphate, alpha-d-galactopyranosyl ester
uridine 5'-pyrophosphate, alpha-d-galactopyranosyl ester (6ci,7ci)
uridine 5'-(trihydrogen pyrophosphate), mono-alpha-d-galactopyranosyl ester (8ci)
uridine diphosphate-d-galactose
uridine 5'-(alpha-d-galactopyranosyl pyrophosphate)
uridine 5'-pyrophosphate, alpha-d-galactosyl ester
uridine 5'-(trihydrogen diphosphate), p'-a-d-galactopyranosyl ester (9ci)
udp-d-galactopyranose
2956-16-3
udp-alpha-d-galactose
udp-alpha-d-galactopyranose
uridine diphosphategalactose
DB03501
uridine-5'-diphosphate-alpha-d-galactose
chebi:67119 ,
CHEMBL439009 ,
[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
bdbm50209668
galactose-uridine-5''-diphosphate
o2hy4wy2w1 ,
unii-o2hy4wy2w1
BMSE001024
uridine 5'-[3-(alpha-d-galactopyranosyl) dihydrogen diphosphate]
SCHEMBL1521203
{[(2r,3s,4r,5r)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[hydroxy({[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphoryl]oxy})phosphinic acid
uridine 5'-pyrophosphate alpha-delta-galactosyl ester
uridine 5'-pyrophosphate d-galactosyl ester
udp-a-d-galactose
udp-alpha-delta-galactose
udp-delta-galactose
uridine pyrophosphate alpha-d-galactopyranosyl ester
uridine pyrophosphate a-d-galactopyranosyl ester
uridine diphosphate-delta-galactose
uridine pyrophosphate alpha-delta-galactopyranosyl ester
uridine 5'-pyrophosphate a-delta-galactosyl ester
uridine 5'-pyrophosphate a-delta-galactopyranosyl ester
udp-delta-galactopyranose
uridine 5'-pyrophosphate alpha-d-galactosyl ester
uridine 5'-pyrophosphate a-d-galactopyranosyl ester
uridine pyrophosphate a-delta-galactopyranosyl ester
uridine 5'-pyrophosphate a-d-galactosyl ester
uridine 5'-(alpha-delta-galactopyranosyl pyrophosphate)
[(2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl dihydrogen diphosphate (non-preferred name)
HSCJRCZFDFQWRP-ABVWGUQPSA-N
DTXSID60903962
((2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl ((2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl) dihydrogen diphosphate
Q259015
uridine 5'-(.alpha.-d-galactopyranosyl pyrophosphate)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These novel data highlight the applicability of NMR-based metabonomics in elucidating multicompartmental metabolic consequences of toxicity and toxic salvage."( The mechanism of galactosamine toxicity revisited; a metabonomic study.
Clayton, TA; Coen, M; Holmes, E; Hong, YS; Lindon, JC; Nicholson, JK; Pearce, JT; Reily, MD; Robertson, DG; Rohde, CM, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" This study demonstrates that after the induction of diabetes there is a rapid increase in the bioavailability of substrates utilized in the synthesis of glycoproteins and glycosaminoglycans."( Effects of early diabetes on uridine diphosphosugar synthesis in the rat renal cortex.
Cortes, P; Dumler, F; Levin, NW; Sastry, KS; Verghese, CP, 1982
)
0.26

Dosage Studied

ExcerptRelevanceReference
" The correlation between galactosyltransferase activities and chromosome 17 dosage indicates that the structural or regulatory gene for these enzymes are located on chromosome 17."( Several galactosyltransferase activities are associated with mouse chromosome 17.
Furukawa, K; Roth, S; Sawicki, J, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
UDP-D-galactoseA UDP-sugar having D-galactose as the sugar component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (18)

PathwayProteinsCompounds
Galactose Metabolism1234
Nucleotide Sugars Metabolism817
Lactose Synthesis1015
Galactosemia1234
Galactosemia II (GALK)817
Galactosemia III817
Congenital Disorder of Glycosylation CDG-IId1015
GLUT-1 Deficiency Syndrome1015
Galactose Degradation/Leloir Pathway1318
Colanic Acid Building Blocks Biosynthesis1723
Leloir Pathway612
Amino Sugar and Nucleotide Sugar Metabolism2229
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Disorders of galactose metabolism07
1p36 copy number variation syndrome28
UDP-glucose conversion04
Lactose degradation and galactose metabolism07
Biochemical pathways: part I0466

Protein Targets (3)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2Y purinoceptor 14Homo sapiens (human)EC50 (µMol)0.67000.16000.37650.6700AID286300; AID450300
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
lactose biosynthetic processBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
protein N-linked glycosylationBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
lipid metabolic processBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
oligosaccharide biosynthetic processBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
protein galactosylationBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
positive regulation of circulating fibrinogen levelsBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
carbohydrate metabolic processN-acetyllactosaminide alpha-1,3-galactosyltransferaseBos taurus (cattle)
protein glycosylationN-acetyllactosaminide alpha-1,3-galactosyltransferaseBos taurus (cattle)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 14Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activityBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
N-acetyllactosamine synthase activityBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
lactose synthase activityBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
protein bindingBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
manganese ion bindingBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
UDP-galactosyltransferase activityBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
metal ion bindingN-acetyllactosaminide alpha-1,3-galactosyltransferaseBos taurus (cattle)
N-acetyllactosaminide 3-alpha-galactosyltransferase activityN-acetyllactosaminide alpha-1,3-galactosyltransferaseBos taurus (cattle)
G protein-coupled UDP receptor activityP2Y purinoceptor 14Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
Golgi trans cisternaBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
extracellular spaceBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
Golgi apparatusBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
external side of plasma membraneBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
basolateral plasma membraneBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
desmosomeBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
filopodiumBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
brush border membraneBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
Golgi cisterna membraneBeta-1,4-galactosyltransferase 1 Bos taurus (cattle)
Golgi cisternaN-acetyllactosaminide alpha-1,3-galactosyltransferaseBos taurus (cattle)
Golgi cisterna membraneN-acetyllactosaminide alpha-1,3-galactosyltransferaseBos taurus (cattle)
plasma membraneP2Y purinoceptor 14Homo sapiens (human)
membraneP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID286300Agonist activity at human P2Y14 expressed in COS7 cells assessed as stimulation of PLC-mediated [3H]inositol hydrolysis2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.
AID677179Activity of bovine alpha-1,3-GalT by HPLC analysis2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Inhibition of galactosyltransferases by a novel class of donor analogues.
AID450303Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells up to 10 uM2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
AID677178Activity of bovine beta-1,4-GalT by HPLC analysis2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Inhibition of galactosyltransferases by a novel class of donor analogues.
AID677172Binding affinity to Neisseria meningitidis alpha-1,4-GalT after 15 mins by competitive binding assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Inhibition of galactosyltransferases by a novel class of donor analogues.
AID450300Agonist activity at human P2Y14 receptor expressed in human COS7 cells2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
AID1346390Human P2Y14 receptor (P2Y receptors)2009The Journal of pharmacology and experimental therapeutics, Jul, Volume: 330, Issue:1
Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems.
AID1346395Rat P2Y14 receptor (P2Y receptors)2001Genomics, Dec, Volume: 78, Issue:3
Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs.
AID1346389Mouse P2Y14 receptor (P2Y receptors)2001Genomics, Dec, Volume: 78, Issue:3
Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs.
AID1346914Human GPR17 (Class A Orphans)2010British journal of pharmacology, Mar, Volume: 159, Issue:5
Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants.
AID1346857Mouse GPR17 (Class A Orphans)2008PloS one, , Volume: 3, Issue:10
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
AID1346914Human GPR17 (Class A Orphans)2006The EMBO journal, Oct-04, Volume: 25, Issue:19
The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (561)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990232 (41.35)18.7374
1990's134 (23.89)18.2507
2000's124 (22.10)29.6817
2010's63 (11.23)24.3611
2020's8 (1.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.16 (24.57)
Research Supply Index6.35 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.18%)5.53%
Reviews11 (1.94%)6.00%
Case Studies8 (1.41%)4.05%
Observational0 (0.00%)0.25%
Other548 (96.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]